ImmunityBio, Inc. IBRX Total Cash, Cash Equivalents, and Restricted Cash (Inclusive)
Total Cash, Cash Equivalents, and Restricted Cash (Inclusive) at other companies
Other financials
Where this comes from
Reported directly by ImmunityBio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations.
The official record: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about ImmunityBio, Inc.'s total cash, cash equivalents, and restricted cash (inclusive).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ImmunityBio, Inc.'s total cash, cash equivalents, and restricted cash (inclusive)?
- ImmunityBio, Inc. (IBRX) reported total cash, cash equivalents, and restricted cash (inclusive) of $206.47M in Q1 2026.
- How has ImmunityBio, Inc.'s total cash, cash equivalents, and restricted cash (inclusive) changed year-over-year?
- ImmunityBio, Inc.'s total cash, cash equivalents, and restricted cash (inclusive) increased by 237.7% year-over-year, from $61.14M to $206.47M.
- What is the long-term trend for ImmunityBio, Inc.'s total cash, cash equivalents, and restricted cash (inclusive)?
- Over 5 years (2020 to 2025), ImmunityBio, Inc.'s total cash, cash equivalents, and restricted cash (inclusive) has grown at a 20.6% compound annual growth rate (CAGR), from $35.09M to $89.43M.